Výsledky vyhledávání - "Ulrike Zoellner"

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours

Autor: D Berton Rigaud, Fabien Calvo, Mario Campone, D. Bootle, Emmanuelle Bourbouloux, N. Shand, Vincent Levy, Catherine Dutreix, Ulrike Zoellner, Eric Raymond

Publikováno v: British Journal of Cancer

Everolimus displays antiproliferative effects on cancer cells, yields antiangiogenic activity in established tumours, and shows synergistic activity with paclitaxel in preclinical models. This study assessed the safety and the pharmacokinetic interac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eed272b424d82371c6c9b7c8e1f9d95a
https://doi.org/10.1038/sj.bjc.6604851

Zobrazit plný text záznamu

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

Autor: Suzanne F. Jones, Cathryn Brock, N. Shand, Howard A. Burris, Daniel Rea, John M. Kovarik, Sandrine Faivre, Eric Raymond, Anne O'Donnell, Ian Judson, Heidi Lane, Ulrike Zoellner, Vassiliki A. Papadimitrakopoulou, Katharine Hazell

Publikováno v: Journal of Clinical Oncology. 26:1588-1595

PurposeTo identify the optimal regimen and dosage of the oral mammalian target of rapamycin inhibitor everolimus (RAD001).MethodsWe performed a dose-escalation study in advanced cancer patients administering oral everolimus 5 to 30 mg/wk, with pharma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4be08396e02bbb2a0f09ab48470092ae
https://doi.org/10.1200/jco.2007.14.0988

Zobrazit plný text záznamu

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors

Purpose Everolimus is a selective mammalian target of rapamycin (mTOR) inhibitor with promising anticancer activity. In order to identify a rationally based dose and schedule for cancer treatment, we have conducted a tumor pharmacodynamic phase I stu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60503b03b5c42e7b8e28fc99601e5a48
http://hdl.handle.net/11591/372603

Zobrazit plný text záznamu

The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics

Autor: Pui Tang, Luc Dirix, Chiaki Tanaka, Ulrike Zoellner, Christos Sotiriou, Ahmad Awada, Jutta Steinseifer, Christel Fontaine, Carine Wouters, Fatima Cardoso, Jacques De Greve, Martine Piccart

Purpose To investigate the safety and pharmacokinetics (PK) of combined treatment with letrozole and the oral mTOR inhibitor RAD001 in patients with metastatic breast cancer stable or progressing after ⩾4 months on letrozole alone. Methods Eighteen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1663c398169e1a50ba6d060668a752a5
https://hdl.handle.net/20.500.14017/479df5c7-07f1-4c5f-a4de-83cc1425c226

Zobrazit plný text záznamu

Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study

Autor: Susan M. Blaney, Marianne Rosamilia, Renaud Capdeville, Mark Krailo, Mark Bernstein, Bin Peng, Martine Therrien, Ulrike Zoellner, Martin A. Champagne, Wenchun Qu

Publikováno v: Blood. 104(9)

The purpose of this study was to determine dose-limiting toxicities and pharmacokinetics of imatinib in children with refractory or recurrent Philadelphia chromosome-positive (Ph+) leukemias. Oral imatinib was administered daily at dose levels rangin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86fc47a04f33a9185b9a28ca55b06a67
https://pubmed.ncbi.nlm.nih.gov/15231574

Zobrazit plný text záznamu

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

Publikováno v: The New England journal of medicine. 346(9)

Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase.A total of 532 patients with late--chronic-phase CML

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::352c4b1459afa210623f00172de193a2
https://pubmed.ncbi.nlm.nih.gov/12167692

Zobrazit plný text záznamu

Results of a phase 1 clinical trial investigating a combination of the oral mTOR-inhibitor Everolimus (E, RAD001) and Gemcitabine (GEM) in patients (pts) with advanced cancers

Autor: Daniel Rea, Ian Judson, A. O'Donnell, Ulrike Zoellner, C. Brock, N. Knowlton, Katharine Hazell, Simon Pacey, N. Shand, N. Steven

Publikováno v: Journal of Clinical Oncology. 22:3120-3120

3120 Background: Pre-clinical studies of E have shown dose-dependent inhibition of tumor growth, reduced tumor vascularity and potentiation of the activity of a number of cytotoxics, particularly GEM. This phase 1 study investigated E alone and then

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4e7411baeb104733a76981ec8162af82
https://doi.org/10.1200/jco.2004.22.90140.3120

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání